Market Overview
The USA glucose monitoring devices market reached USD 7.34 billion in 2025 and is forecast to reach USD 18.36 billion by 2035, expanding at a CAGR of 9.6% from 2026 to 2035. The market covers continuous glucose monitoring systems, self-monitoring blood glucose meters, test strips, lancets, sensors, transmitters, receivers, and related software used to measure, display and share glucose data.
Continuous glucose monitoring has changed the market from periodic measurement to recurring biosensor access. Revenue is increasingly generated by sensors replaced every 10, 14, or 15 days, implantable systems with longer wear, application subscriptions, data services, and integration with insulin-delivery systems. This creates stronger lifetime revenue than a low-cost meter placement, but it also moves competition toward payer coverage, pharmacy availability, interoperable software and the ability to retain users after the first sensor cycle.
The next expansion pool is not limited to people with Type 1 diabetes or intensive insulin therapy. Clinical evidence, over-the-counter products and broader product labeling are opening CGM to adults with Type 2 diabetes who do not use insulin and to people seeking metabolic insights. This wider population changes the sales model: physician prescribing and durable medical equipment remain important, while retail pharmacy, direct-to-consumer education and app-led onboarding gain influence.
Key Highlights
- Continuous glucose monitoring systems generated an estimated 72% of 2025 revenue, equal to USD 5.28 billion, reflecting repeated sensor replacement and growing use beyond intensive insulin therapy.
- Self-monitoring blood glucose products retained 28%, or USD 2.06 billion, through test-strip consumption, lower acquisition cost, confirmatory testing and use by people who do not require continuous data.
- Type 2 diabetes represented an estimated 63% of device revenue, equal to USD 4.62 billion, because of the condition's large diagnosed population and expanding CGM access among insulin and non-insulin users.
- Home settings accounted for 79% of market revenue, or USD 5.80 billion, as smartphones, remote data sharing and mail or pharmacy fulfillment shift monitoring away from clinical sites.
- Retail and specialty pharmacies handled an estimated 45% of sales, while durable medical equipment and mail-order suppliers captured 36%.
- CGM differentiation now depends on wear duration, accuracy, alarm performance, automated insulin-delivery compatibility, app usability and payer access rather than sensor size alone.
- The strongest growth constraint is incomplete access: coverage rules, out-of-pocket cost, training gaps and sensor discontinuation can prevent a cleared product from becoming sustained use.
Market Definition and Scope
Continuous glucose monitoring systems measure glucose in interstitial fluid through a wearable or implantable sensor and transmit readings to a receiver, smartphone or compatible insulin-delivery system. The category includes real-time CGM, intermittently scanned CGM, professional CGM and over-the-counter biosensors. Revenue covers sensors, transmitters, receivers and software where the digital component is sold with or directly supports the monitoring system.
Self-monitoring blood glucose systems use a meter, disposable test strip, lancet and a capillary blood sample. The report includes meters and recurring consumables but excludes laboratory chemistry analyzers, glycated hemoglobin tests, insulin pumps sold without a glucose sensor and stand-alone wellness applications that do not use a regulated glucose biosensor.
Reimbursement and Route-to-Market Changes
Pharmacy access is reducing an old adoption barrier
CGM was historically supplied through durable medical equipment channels that required documentation, fulfillment coordination and shipment. Pharmacy coverage has made initiation more similar to other prescriptions and lets users collect sensors with medications. However, access is still fragmented. A plan may cover the same product under the pharmacy benefit, medical benefit or both, with different copays and authorization rules. Manufacturers and distributors must route each prescription to the lowest-friction covered channel.
Medicare expansion changed the addressable population
Medicare coverage extends to eligible beneficiaries who use insulin or have a documented history of problematic hypoglycemia, subject to coverage requirements. This widened CGM access beyond people using multiple daily insulin injections. The commercial effect is significant because older adults represent a large diabetes population, but suppliers still need prescriber documentation, covered receiver requirements where applicable and reliable resupply.
Over-the-counter CGM creates a separate market architecture
Over-the-counter systems remove the prescription step for intended users, creating direct digital onboarding and retail purchase. Dexcom Stelo and Abbott Lingo demonstrate two different propositions: diabetes-oriented glucose insight for adults not using insulin and consumer metabolic feedback. The category can generate new users, but it also brings higher price transparency and greater dependence on app engagement. Repeat purchase will depend on whether users receive useful decisions from the data after initial curiosity declines.
Integrated delivery systems reward interoperability
For insulin users, a CGM can be the sensing layer of an automated insulin-delivery system. Compatibility with pumps and dosing algorithms increases clinical value and user retention. It also raises qualification requirements because communication reliability, alarm behavior, cybersecurity and sensor accuracy affect treatment decisions. Suppliers without pump partnerships must compete more heavily through stand-alone experience, broad access or specialized wear duration.
Technology and Buying Shifts
Wear duration is becoming an economic lever
Longer sensor wear reduces the number of insertions, packages and refill events, but it does not automatically reduce annual price. Dexcom's 15-day product extends disposable sensor life, while Eversense 365 uses an implantable sensor designed for one year. These models create different revenue, training and service requirements. Disposable CGM depends on frequent resupply; implantable CGM requires a trained clinician for insertion and removal but reduces replacement frequency.
Software is moving from display to intervention
Modern CGM applications show trend arrows, time in range, alerts and retrospective reports. The competitive frontier is pattern recognition, personalized summaries, nutrition guidance and the ability to share actionable information with clinicians and caregivers. Poor alert settings or excessive notifications can cause fatigue, so more analytics do not always improve retention. Software must help users decide what to do, not simply produce more charts.
Non-insulin Type 2 evidence is changing prescribing
Adults with Type 2 diabetes who do not use insulin are a much larger population than intensive insulin users. Their use case centers on food, activity, medication response and behavior change rather than hypoglycemia alarms alone. Evidence must show that CGM produces durable glycemic or behavioral improvement after the sensor is removed or replaced. Without coaching or a defined care plan, short-term data visibility may not translate into sustained value.
Accuracy remains inseparable from usability
Mean absolute relative difference is commonly used to describe accuracy, but practical trust also depends on startup time, compression effects, signal loss, medication interference, adhesion and performance during rapid glucose change. A sensor that is analytically strong but difficult to apply or keep attached can create replacement costs and discontinuation. Manufacturers therefore compete across chemistry, algorithms, adhesive systems, applicators and support.
Market Dynamics
Driver: increasing diabetes burden and monitoring intensity
The United States has a large diagnosed diabetes population, with Type 2 diabetes accounting for most cases. Monitoring demand increases when insulin is initiated, treatment changes, pregnancy raises risk or a clinician needs to understand glucose variability that periodic testing misses. The revenue effect is strongest when a person moves from occasional finger-stick testing to year-round CGM use.
Driver: clinical use of time-in-range data
CGM provides a profile of glucose exposure, variability and hypoglycemia that a single meter reading cannot capture. Time in range gives clinicians and users a more immediate management measure than waiting for the next glycated hemoglobin result. This supports remote review and therapy adjustment, particularly when data can enter the clinical workflow without manual download.
Restraint: cost and uneven coverage
Sensors create recurring annual expense. Commercial plans, Medicare and Medicaid programs differ in eligibility, preferred brands, authorization and channel. People who change insurance may face a different product or supply pathway. Cash-pay products increase choice but can exclude price-sensitive users, widening the gap between technical availability and continuous use.
Restraint: training and discontinuation
First-time users need help with insertion, alarms, interpretation, skin reactions and data sharing. A device can be abandoned if early readings create anxiety or if the user cannot connect the sensor to a phone. Pharmacy availability alone does not solve this problem. Scalable virtual training and rapid sensor-replacement support are essential to protect refill revenue.
Opportunity: employer and value-based diabetes programs
Health plans and employers can combine CGM with coaching, medication management and outcomes contracts. These programs can reach high-risk adults who do not qualify through traditional insulin-based pathways. Successful models must demonstrate reduced acute events, improved glycemic measures or lower total cost rather than engagement alone.
Opportunity: continuous ketone and multi-analyte sensing
Abbott's Libre Duo has secured CE Mark for simultaneous glucose and ketone measurement but is not cleared for U.S. sale. The concept demonstrates how glucose biosensors can expand into acute-risk monitoring, particularly diabetic ketoacidosis. Future U.S. products that add clinically relevant analytes could raise revenue per sensor and create new care protocols.
Market Segmentation
The following percentage allocations divide the USD 7.34 billion 2025 market by product, component, diabetes type, end user, channel and payer. They are analytical revenue estimates based on device use, replacement frequency, company product mix, coverage and channel structure; they are not unit shipments or company-disclosed U.S. segment sales.
By Product Type
Continuous glucose monitoring systems held an estimated 72% share in 2025, equal to USD 5.28 billion. Repeated sensor replacement accounts for most revenue, followed by transmitters, receivers and integrated software. CGM's lead reflects wide adoption in Type 1 diabetes, stronger use among insulin-treated Type 2 patients and entry into non-insulin and over-the-counter segments.
Self-monitoring blood glucose systems accounted for 28%, or USD 2.06 billion. Test strips produced most SMBG revenue because meters are often discounted to create recurring strip consumption. SMBG remains important for people who test less frequently, users who cannot access CGM, confirmatory checks, inpatient workflows and situations where sensor readings do not match symptoms.
By Component
Sensors and test strips represented an estimated 76% of total market revenue, equal to USD 5.58 billion. Their replacement cycle makes them the economic center of both CGM and SMBG. Within CGM, disposable and implantable sensors accounted for close to 84% of category revenue, while transmitters, receivers and insertion hardware supplied the remainder.
Meters, receivers and transmitters held 15%, or USD 1.10 billion. Their share is declining as smartphones replace dedicated displays and some CGM designs integrate transmitter functions into the disposable sensor. Lancets, control solutions, applicators and other accessories represented 9%, equal to USD 0.66 billion.
By Diabetes Type and Use Case
Type 2 diabetes generated an estimated 63% of 2025 revenue, or USD 4.62 billion. Its large patient population offsets lower monitoring intensity per person. Insulin-treated users form the largest existing CGM opportunity, while adults not using insulin offer the widest expansion pool.
Type 1 diabetes accounted for 28%, equal to USD 2.06 billion. Revenue per user is high because continuous data, alerts and pump integration support daily insulin decisions. Gestational diabetes, prediabetes and other glucose-management uses held 9%, or USD 0.66 billion. Over-the-counter biosensors may increase this share, although wellness use has different retention and reimbursement economics.
By End User
Home settings dominated with 79% of 2025 revenue, representing USD 5.80 billion. Sensors, test strips and connected applications are used repeatedly outside medical facilities. Caregivers and clinicians can review shared data without being physically present, strengthening the home as the primary consumption site.
Hospitals and diagnostic centers held 13%, or USD 0.95 billion. Their demand includes inpatient meters, professional CGM, confirmatory testing and discharge programs. Physician offices and ambulatory clinics accounted for 8%, equal to USD 0.59 billion. These sites influence product initiation, training and report interpretation even when the device is purchased elsewhere.
By Distribution Channel
Retail and specialty pharmacies accounted for an estimated 45% of revenue, equal to USD 3.30 billion. Electronic prescribing, broad pharmacy footprints and benefit adjudication support this lead. Durable medical equipment and mail-order suppliers held 36%, or USD 2.64 billion, with a strong role in Medicare and recurring home delivery.
Hospital and clinic procurement represented 12%, equal to USD 0.88 billion. Direct-to-consumer and other channels contributed 7%, or USD 0.51 billion. Direct sales are positioned to gain share as over-the-counter CGM expands, but retailers and e-commerce pharmacies may still complete fulfillment.
By Payer
Commercial insurance generated an estimated 49% of 2025 revenue, equal to USD 3.60 billion. Employer-sponsored plans cover a large working-age population but differ in eligibility and preferred products. Medicare held 29%, or USD 2.13 billion, supported by expanded eligibility and high diabetes prevalence among older adults.
Medicaid accounted for 15%, equal to USD 1.10 billion. Access varies by state, producing meaningful geographic differences in CGM uptake. Cash payment, employer programs and other funding supplied 7%, or USD 0.51 billion. This segment includes over-the-counter biosensors and users paying outside insurance.
State and Subregional Analysis
South
The South held the largest estimated share at 38% in 2025, equal to USD 2.79 billion. Texas represented 9% of the national market, or USD 0.66 billion, while Florida accounted for 7%, or USD 0.51 billion. High diabetes burden and large Medicare and Medicaid populations support demand, but rural provider access and state-level coverage differences create uneven CGM penetration.
West
The West captured 24% of revenue, representing USD 1.76 billion. California alone held an estimated 14% of the U.S. market, equal to USD 1.03 billion, supported by population scale, integrated health systems and technology adoption. Washington, Arizona and Colorado added demand through commercial coverage and diabetes programs. The region also contains major CGM developers, strengthening clinical and digital-health partnerships.
Midwest
The Midwest accounted for 21%, or USD 1.54 billion in 2025. Illinois and Ohio each represented close to 4% of national revenue, equal to USD 0.29 billion per state. Health-system consolidation can support standardized CGM pathways, while rural areas depend more heavily on primary care, pharmacy training and remote endocrinology.
Northeast
The Northeast generated 17% of revenue, equal to USD 1.25 billion. New York held an estimated 7% of the national market, or USD 0.51 billion, with Pennsylvania, Massachusetts and New Jersey providing additional demand. Dense specialist networks and academic centers support advanced use, but payer variation still affects product choice and channel.
Competitive Landscape
Abbott and Dexcom lead stand-alone CGM, while Medtronic competes through an integrated pump-and-sensor ecosystem. Senseonics differentiates through a clinician-inserted sensor designed for 365-day wear. LifeScan, Ascensia, Roche, ARKRAY, Nova Biomedical and other companies remain relevant in SMBG, professional testing and supporting services.
The market does not behave like a simple device comparison. A product must secure FDA clearance, payer coverage, pharmacy or DME availability, prescriber confidence, smartphone compatibility and user retention. Pump partnerships can lock a sensor into an automated insulin-delivery ecosystem. Over-the-counter clearance creates another route, but it transfers more responsibility for education and continued engagement to the application.
Key Players
Abbott Diabetes Care, Dexcom, Medtronic, Senseonics, Ascensia Diabetes Care, LifeScan, Roche Diabetes Care, ARKRAY, AgaMatrix, Nova Biomedical, ACON Laboratories, i-SENS and other glucose-monitoring manufacturers and digital diabetes platforms.
Detailed Company Profiles
Abbott Laboratories
Abbott's diabetes-care business is built around the FreeStyle Libre sensor platform. Its U.S. portfolio includes prescription CGM systems and Lingo, an over-the-counter biosensor intended for adults seeking glucose insight. Libre systems provide sensor readings, trend data, alarms on supported products and digital reports that can be shared with clinicians. The platform is also being integrated with automated insulin-delivery partners.
Abbott stated in May 2026 that Libre technology was used by more than 8 million people across over 60 countries. Its scale supports sensor manufacturing, payer contracting and broad pharmacy distribution. The company's competitive strength is a high-volume sensor platform spanning diabetes treatment and consumer biowearables. Libre Duo, which continuously measures glucose and ketones, secured CE Mark in May 2026 but was not cleared for U.S. sale at the time of the announcement.
Abbott's U.S. opportunity is to expand pharmacy access, increase automated insulin-delivery compatibility and convert more Type 2 users to continuous monitoring. Its challenge is maintaining differentiation as wear times lengthen and rivals add coaching and prevention-oriented applications.
Dexcom, Inc.
Dexcom is a focused glucose-biosensing company. Its U.S. portfolio includes Dexcom G7, Dexcom G7 15 Day and Stelo. G7 supports diabetes management and integrations with compatible insulin-delivery systems. The 15-day version extends wear for eligible adults, while Stelo is an over-the-counter glucose biosensor for adults who do not use insulin.
Dexcom reported fiscal 2025 revenue of USD 4.65 billion, with U.S. revenue forming the largest geographic contribution. Its commercial model is based on recurring sensor sales, pharmacy and DME access, pump partnerships and data applications. The company is expanding beyond intensive insulin therapy through evidence in non-insulin Type 2 diabetes and the redesigned Stelo application.
In June 2026, Dexcom announced an agreement to acquire Nutrisense, adding registered-dietitian access, nutrition guidance and behavior-change support. This moves the company from glucose display toward an intervention and coaching ecosystem.
Medtronic plc
Medtronic competes through an integrated diabetes ecosystem combining insulin pumps, algorithms, infusion products and continuous glucose sensors. Relevant U.S. offerings include MiniMed systems, Guardian sensor technology and Simplera Sync, depending on active FDA labeling and system compatibility. Its main advantage is control of both sensing and insulin delivery within a closed-loop pathway.
The company serves users who require intensive insulin management and values sensor performance in relation to automated dosing, not only stand-alone display. Its installed pump base creates recurring demand for sensors and supplies. Medicare access and product clearances can therefore influence both monitoring and pump revenue.
Medtronic's competitive position is strongest where users prefer a unified manufacturer for pump, sensor and algorithm. The challenge is matching stand-alone CGM leaders on sensor wear, insertion experience, smartphone features and pharmacy convenience while preserving closed-loop reliability.
Senseonics Holdings, Inc.
Senseonics develops the Eversense implantable continuous glucose monitoring platform. Eversense 365 is designed to provide one year of sensor wear for adults, using a sensor inserted under the skin by a trained healthcare professional and a removable external transmitter. The architecture differs from disposable sensors and reduces the number of sensor insertions across a year.
The company reported 2025 revenue through its Eversense franchise and is investing in U.S. commercial expansion, app development and automated insulin-delivery integration. Its model depends on trained insertion providers, patient referral, reimbursement and the ability to coordinate the procedure with sensor and transmitter supply.
In May 2026, Senseonics closed a USD 92 million public offering and expanded borrowing capacity to USD 140 million. It followed with a Welldoc application partnership in June and a Beta Bionics integration partnership in September. These moves address capital, software and closed-loop compatibility, the three main requirements for scaling an implantable CGM platform.
Recent Developments: March 15–September 15, 2026
On September 14, 2026, Senseonics announced a partnership with Beta Bionics to integrate Eversense 365 with the iLet Bionic Pancreas. The agreement is commercially important because automated insulin-delivery compatibility can make a long-wear implantable sensor relevant to pump users who previously selected disposable CGM ecosystems.
On June 10, 2026, Senseonics and Welldoc partnered on a next-generation Eversense 365 application. The planned app combines implantable CGM data with Welldoc's digital coaching capabilities. The partnership targets a key weakness in glucose monitoring: users receive large data volumes but may not know how to translate patterns into daily action.
On June 8, 2026, the FDA recorded a substantially equivalent decision for Dexcom G7 and Dexcom G7 15 Day. The submission was received on April 29 and decided on June 8, reinforcing the active regulatory pathway for the two G7 configurations. FDA records are relevant to launch planning, labeling and payer review.
On June 4, 2026, Dexcom announced an agreement to acquire Nutrisense and outlined a redesigned Stelo app. The app received FDA clearance in May and adds pattern recognition, AI-supported coaching and personalized summaries. The acquisition adds dietitian and nutrition-coaching capacity, extending Dexcom's commercial model beyond sensor supply.
On May 27, 2026, Abbott secured CE Mark for Libre Duo and Libre Duo 10 Day. The systems continuously measure glucose and ketones in one sensor and are designed for integration with Libre digital services and automated insulin delivery. Abbott stated that the products were not cleared or available in the United States, so the development is a pipeline signal rather than current U.S. sales.
On May 4, 2026, Senseonics closed a USD 92 million public offering and expanded its debt capacity. The financing provides resources for commercial execution and development around the Eversense platform. For a smaller CGM manufacturer, access to capital directly affects provider training, patient acquisition, inventory and integration work.
In March 2026, Abbott reported trial evidence for Libre use in adults with Type 2 diabetes treated with basal insulin. The study strengthens the case for CGM in a large population that does not use intensive insulin regimens. The commercial relevance lies in future prescribing and coverage discussions for earlier monitoring.
No development dated before March 15, 2026, is included.
Market Opportunities and Unmet Needs
The largest expansion opportunity is sustained CGM use among adults with Type 2 diabetes who do not use intensive insulin. Success requires more than clearance. Clinicians need evidence, simple prescribing and a clear response plan; users need training and affordable refills; payers need proof that monitoring changes outcomes or total cost.
Pharmacy-led initiation is another opportunity. Pharmacists can support application, interpretation and resupply, particularly where endocrinology access is limited. Manufacturers can strengthen this route with concise onboarding, device replacement protocols and software that allows data sharing without complex account setup.
Unmet need remains for stronger adhesion across skin types, fewer false or non-actionable alarms, broader phone compatibility, low-burden data sharing and affordable access during insurance transitions. Implantable and dual-analyte sensors address different pain points, but they introduce insertion or regulatory requirements. The winning product will balance accuracy, wear, service and access rather than maximizing one specification.
Report Scope
| Category | Coverage |
| Product | Continuous glucose monitoring and self-monitoring blood glucose systems |
| Indication | Type 1 diabetes, Type 2 diabetes, gestational diabetes, prediabetes and other glucose-management uses |
| Channel | Retail and specialty pharmacies, DME and mail order, institutional procurement and direct sales |
| Payer | Commercial insurance, Medicare, Medicaid, cash and employer programs |
Strategic Takeaways
- Prioritize recurring sensor economics and user retention rather than reporting hardware placements as the main growth indicator.
- Build separate access strategies for commercial insurance, Medicare, Medicaid and cash-pay over-the-counter users.
- Treat non-insulin Type 2 diabetes as a distinct evidence and onboarding market, not a simple extension of intensive insulin therapy.
- Make pharmacy availability, electronic prescribing and benefit verification part of product launch planning.
- Design software around actionable patterns, clinician review and automated insulin delivery instead of adding data without a care response.
- Protect continuity through diversified sensor manufacturing, predictable launches and transparent replacement support.
- Monitor implantable and dual-analyte sensors because longer wear and glucose-ketone measurement can change replacement frequency and clinical value.
